- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as should have been, said Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
For those who missed it, what were some of the highlights from the House Energy and Commerce Committee hearing regarding the HHS budget for fiscal year 2023?
I think the highlights of that hearing mostly were, from a Biosimilars Forum perspective, it's what we didn't hear. We didn't hear enough about how HHS is going to do more to gain cost savings using biosimilars. How they're going to do more policies that we've been advocating for for years, [addressing] market barriers and improving access to biosimilars.
So, I think that was the most surprising thing for the Biosimilar Forum and our members. We heard a little bit about biosimilars. We've been saying, "Look, there's a solution right here to reduce prescription drug cost overall." It's such a critical, critical year for biosimilars, especially with the 7 biosimilars for Humira [adalimumab] launching next year.
So, we're going to go back and ask HHS to continue to support biosimilars and continue to work with them, especially on those upcoming launches. So, that was our takeaway, and it's now a greater priority for the Forum to get back to HHS.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
